Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Quote | Allakos Inc. (NASDAQ:ALLK)
Last: | $0.9052 |
---|---|
Change Percent: | 0.11% |
Open: | $0.9141 |
Close: | $0.9052 |
High: | $0.96 |
Low: | $0.8702 |
Volume: | 560,516 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
News | Allakos Inc. (NASDAQ:ALLK)
2024-06-26 14:34:42 ET More on Allakos Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos Read the full article on Seeking Alpha For further details see: Allakos drops after early-...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
Message Board Posts | Allakos Inc. (NASDAQ:ALLK)
Subject | By | Source | When |
---|---|---|---|
znewcar1: ALLK 26% v21,7M c5.7801 f54,84M H6.13 ML3.45 yL off the 20dma | znewcar1 | investorshangout | 09/19/2022 9:36:59 PM |
znewcar1: After falling you talk about adding this @ $8. LL2.54 ML3.9 HOD6.31 bo 4 and pushed to HOD | znewcar1 | investorshangout | 08/31/2022 11:18:27 PM |
THIS POS IS A SCAM GONNA GO | RobH1312 | investorshub | 03/10/2022 8:48:57 PM |
We will go short on this one. | REAGAN | investorshub | 02/20/2022 6:11:03 PM |
Agree, the next couple weeks should be very | FROZENFLAME | investorshub | 02/20/2022 12:40:20 AM |
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...